Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Proteon Therapeutics stock

Own Proteon Therapeutics stock in just a few minutes.

Fact checked

Proteon Therapeutics, Inc is an other business based in the US. Proteon Therapeutics shares (PRTO) are listed on the NASDAQ and all prices are listed in US Dollars. Proteon Therapeutics employs 17 staff and has a market cap (total outstanding shares value) of USD$18.5 million.

How to buy shares in Proteon Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Proteon Therapeutics. Find the stock by name or ticker symbol: PRTO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Proteon Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Proteon Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Proteon Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Proteon Therapeutics share price

Use our graph to track the performance of PRTO stocks over time.

Proteon Therapeutics shares at a glance

Information last updated 2020-08-13.
52-week rangeUSD$0.11 - USD$0.435
50-day moving average USD$0.835
200-day moving average USD$1.7147
Wall St. target priceUSD$1
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.139

Buy Proteon Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Proteon Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Proteon Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -63.42%
Return on equity TTM -113.3%
Profit margin 0%
Book value $-0.598
Market capitalisation USD$18.5 million

TTM: trailing 12 months

Shorting Proteon Therapeutics shares

There are currently 123,371 Proteon Therapeutics shares held short by investors – that's known as Proteon Therapeutics's "short interest". This figure is 38.3% down from 199,813 last month.

There are a few different ways that this level of interest in shorting Proteon Therapeutics shares can be evaluated.

Proteon Therapeutics's "short interest ratio" (SIR)

Proteon Therapeutics's "short interest ratio" (SIR) is the quantity of Proteon Therapeutics shares currently shorted divided by the average quantity of Proteon Therapeutics shares traded daily (recently around 152309.87654321). Proteon Therapeutics's SIR currently stands at 0.81. In other words for every 100,000 Proteon Therapeutics shares traded daily on the market, roughly 810 shares are currently held short.

However Proteon Therapeutics's short interest can also be evaluated against the total number of Proteon Therapeutics shares, or, against the total number of tradable Proteon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Proteon Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Proteon Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0114% of the tradable shares (for every 100,000 tradable Proteon Therapeutics shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Proteon Therapeutics.

Find out more about how you can short Proteon Therapeutics stock.

Proteon Therapeutics share dividends

We're not expecting Proteon Therapeutics to pay a dividend over the next 12 months.

Proteon Therapeutics share price volatility

Over the last 12 months, Proteon Therapeutics's shares have ranged in value from as little as $0.11 up to $0.435. A popular way to gauge a stock's volatility is its "beta".

PRTO.US volatility(beta: 0.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Proteon Therapeutics's is 0.6027. This would suggest that Proteon Therapeutics's shares are less volatile than average (for this exchange).

Proteon Therapeutics overview

As of January 9, 2020, Proteon Therapeutics, Inc. was acquired by ArTara Therapeutics, Inc., in a reverse merger transaction. Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site